KMID : 1039420160500020096
|
|
Journal of Pathology and Translational Medicine 2016 Volume.50 No. 2 p.96 ~ p.103
|
|
Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma
|
|
Choi Chang-Hwan
Park Young-Hoon Lim Joo-Han Choi Suk-Jin Kim Lucia Park In-Suh Han Jee-Young Kim Joon-Mee Chu Young-Chae
|
|
Abstract
|
|
|
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy. However, little is known about the impact of abundance of CD20 expression assessed by immunohistochemistry on the clinical outcome of DLBCL. We performed a semi-quantitative immunohistochemical analysis of CD20 expression in DLBCL to examine the prognostic implication of the level of CD20 expression.
Methods: Pre-treatment diagnostic tissue samples from 48 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen were represented in a tissue microarray and immunostained for CD20. The relative abundance of CD20 expression was semi-quantitatively scored using a web-based ImmunoMembrane plug-in. Receiver operating characteristic curve analysis was used to determine a prognostically relevant cut-off score in order to dichotomize the patients into CD20-high versus CD20-low groups.
Results: The levels of CD20 expression were heterogeneous among the patients, with a wide and linear distribution of scores. Patients in CD20-low group showed significantly poor clinical outcome.
Conclusions: The levels of CD20 expression in DLBCL are heterogeneous among the patients with DLBCL. A subgroup of the patients with CD20 expression levels below the cut-off score showed poor clinical outcome.
|
|
KEYWORD
|
|
Antigen, CD20, Lymphoma, large B-cell, Immunohistochemistry, Tissue array analysis
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|